- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04064190
Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
A Phase 2 Study of TGF-β Inhibition (Vactosertib) With Anti-PD-L1 (Durvalumab) in Patients With Advanced or Recurrent Urothelial Carcinoma Failing to Achieve Response With Checkpoint Inhibition
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Phase 2, open-label, non-randomized, two-cohort multi center study with a safety run-in of 6 patients in Cohort 1. It is anticipated that a total of 48 patients will be enrolled.
Durvalumab will be administered with the standard regimen of 1500 mg intravenously (IV) every four weeks. Vactosertib will be administered at a dose of 300 mg PO BID for 5 days per week All treatment will be administered up to two years and the trial is anticipated to be completed over a period of 36 months.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Sunjin Hwang, MD
- Phone Number: +82 2 6938 0206
- Email: sunjin.hwang@medpacto.com
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- University of California San Francisco
-
Contact:
- Larry Fong, Dr
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Comprehensive Cancer Center
-
Contact:
- Gurkamal Chatta, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at enrollment
- Histologically or cytologically documented locally advanced/inoperable or metastatic urothelial bladder carcinoma (UBC), including renal pelvis, ureters, urinary bladder, and urethra.
- Prior anti-PD-(L)1 treatment.
- Measurable disease per RECIST 1.1 assessed by computed tomography (CT) scan or MRI.
- Recurrent disease after any prior platinum-based chemotherapy regimen or ineligible for platinum therapy.
- Adequate organ and marrow function as defined
- Must have a life expectancy of at least 12 weeks.
- Body weight > 30 kg
Exclusion Criteria:
- History of allogeneic organ transplantation.
- Active or prior documented autoimmune or inflammatory disorders
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure .
- History of another primary malignancy
- History of leptomeningeal carcinomatosis.
- History of active primary immunodeficiency.
- Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus .
- Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vactosertib+Durvalumab
Vactosertib will be administered in combination with standard dose of durvalumab every four weeks.
|
Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: 12months
|
ORR by RECIST version 1.1
|
12months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Tumor Response
Time Frame: Overall study period up to 3years
|
TTR by RECIST version 1.1 and iRECIST
|
Overall study period up to 3years
|
Best Response
Time Frame: Overall study period up to 3years
|
Best response (percent of tumor shrinkage) by RECIST version 1.1 and iRECIST
|
Overall study period up to 3years
|
Duration of Response
Time Frame: Overall study period up to 3years
|
DoR by RECIST version 1.1 and iRECIST
|
Overall study period up to 3years
|
Progression Free Survival
Time Frame: 6-month/ 12-month
|
PFS by RECIST version 1.1 and iRECIST
|
6-month/ 12-month
|
Overall survival
Time Frame: 12month
|
OS by RECIST version 1.1 and iRECIST
|
12month
|
Tumor-specific immune responses
Time Frame: Overall study period up to 3years
|
tumor-specific immune responses within on-therapy biopsies measured by increased T cell infiltration and increased IFN-λ signature.
and the correlation with outcome as measured by ORR, TTR, DoR, PFS and OS
|
Overall study period up to 3years
|
Incidence of Treatment-Emergent Adverse Events [Safety and tolerability]
Time Frame: Overall study period up to 3years
|
To assess safety and tolerability of vactosertib administered concurrent with Durvalumab in patients with urothelial carcinoma failing checkpoint inhibition
|
Overall study period up to 3years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MP-VAC-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urothelial Carcinoma Recurrent
-
UroGen Pharma Ltd.Tanner Pharma GroupAvailableUrothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent
-
UroGen Pharma Ltd.RecruitingCarcinoma, Transitional Cell | Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent | Transitional Cell Carcinoma of Renal PelvisUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterRecruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma and other conditionsUnited States
-
Verity Pharmaceuticals Inc.Not yet recruitingBladder Cancer | Urothelial Carcinoma Bladder | Bladder Cancer Recurrent | Neoplasm Recurrence | Urothelial Carcinoma Recurrent | Non-Invasive Bladder Urothelial Carcinoma
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder... and other conditionsUnited States
-
University of California, DavisMerck Sharp & Dohme LLCCompletedRecurrent Bladder Carcinoma | Stage III Urethral Cancer | Stage IV Urethral Cancer | Urethral Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter | Stage III Bladder Urothelial Carcinoma | Recurrent Urothelial Carcinoma of... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
Clinical Trials on Vactosertib(TEW-7197)/ Durvalumab
-
MedPacto, Inc.CompletedHealthy VolunteersKorea, Republic of
-
MedPacto, Inc.Active, not recruitingMetastatic Gastric CancerKorea, Republic of
-
Samsung Medical CenterRecruitingPancreas CancerKorea, Republic of
-
Weill Medical College of Cornell UniversityRecruitingMyeloproliferative NeoplasmUnited States
-
MedPacto, Inc.CompletedMyelodysplastic SyndromesUnited States
-
MedPacto, Inc.Merck Sharp & Dohme LLCActive, not recruitingMetastatic Colorectal Cancer | Gastric Cancer | Gastroesophageal Junction AdenocarcinomaKorea, Republic of
-
MedPacto, Inc.RecruitingOsteosarcomaUnited States, Korea, Republic of
-
Joon Oh ParkRecruitingMetastatic Pancreatic CancerKorea, Republic of
-
MedPacto, Inc.National OncoVentureCompletedAdvanced Stage Solid TumorsUnited States